Aredia(pamidronate disodium), in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases.
Aredia(pamidronate disodium) is indicated for the treatment of patients with moderate to severe Paget's disease of bone.
Aredia (pamidronate disodium) is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma.
Due to the risk of clinically significant deterioration in renal function, which may progress to renal failure, single doses of Aredia(pamidronate disodium) should not exceed 90 mg and the duration of infusion should be no less than 2 hours. Risk factors for the deterioration of renal function include elevated baseline creatinine and multiple cycles of bisphosphonate treatment.
Aredia Side Effects
Osteonecrosis of the Jaw (ONJ) has been reported in patients with cancer receiving treatment including bisphosphonates, chemotherapy, and/or corticosteroids. A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors. While on treatment, these patients should avoid invasive dental procedures if possible.
The most common adverse events in bone metastases clinical trials regardless of causality were as follows: Fluid overload, generalized pain, hypertension, abdominal pain, anorexia, constipation, nausea, vomiting, urinary tract infection, bone pain, fever, back pain, arthrosis, headache, anemia, hypocalcemia, arthralgias, myalgias, and dyspnea.
Aredia(pamidronate disodium) is not recommended in patients with severe renal impairment. Serum creatinine should be measured before each dose and treatment should be withheld for renal deterioration.
Aredia(pamidronate disodium) is excreted intact primarily via the kidney, and the risk of renal adverse reactions may be greater in patients with impaired renal function. Patients who receive Aredia(pamidronate disodium) should have serum creatinine assessed prior to each treatment. In patients receiving Aredia(pamidronate disodium) for bone metastases, who show evidence of deterioration in renal function, Aredia(pamidronate disodium) treatment should be withheld until renal function returns to baseline.
The generic alternative is not manufactured by the company that makes the brand product.
The content on this page has been supplied to canadianpharmacyking by an independent third party contracted to provide information for our website.
canadianpharmacyking relies on these third parties to create and maintain this information and cannot guarantee the medical efficacy, accuracy or reliability of the information that has been provided to us.
If you require any advice or information about the drugs on this page, a medical condition or treatment advice, you should always speak to a health professional.
Please note that not all products, including any referenced on this page, are shipped by our affiliated Canadian Pharmacy.
We affiliate with other dispensaries that ship products to our customers from the following jurisdictions: Canada, Singapore, New Zealand, Turkey, Mauritius, India, and the United Kingdom.
The items in your order may be shipped from any of the above jurisdictions.
The products are sourced from various countries as well as those listed above. Rest assured, we only affiliate with our authorized dispensaries that procure products through reliable sources.